Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.

Abstract

Neurological soft-sign abnormalities have been implicated in obsessive-compulsive disorder (OCD). This first comprehensive data analysis evaluated the association between baseline neurological soft signs and treatment response in 117 OCD patients treated with controlled-release fluvoxamine in a double-blind placebo-controlled trial. Total and right-sided soft signs for the responders and the nonresponders did not differ significantly. Left-sided visuospatial soft signs were significantly increased in treatment nonresponders compared to responders. These subtle neurological abnormalities may implicate a potential subgroup of OCD patients with poorer treatment response. This may have treatment implications and therefore serve as a screening tool in OCD.

• Authors: Eric Hollander, Alicia Kaplan, James Schmeidler, Haichen Yang, David Li, Lorrin M Koran, Luigi M Barbato
• Journal: The Journal of neuropsychiatry and clinical neurosciences (J Neuropsychiatry Clin Neurosci) Vol. 17 Issue 4 Pg. 472-7 ( 2005) ISSN: 0895-0172 [Print] United States
• PMID: 16387985 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Serotonin Uptake Inhibitors
• Fluvoxamine

Topics

• Double-Blind Method
• Fluvoxamine (therapeutic use)
• Humans
• Obsessive-Compulsive Disorder (drug therapy, physiopathology)
• Personality Inventory (statistics & numerical data)
• Psychiatric Status Rating Scales (statistics & numerical data)
• Selective Serotonin Reuptake Inhibitors (therapeutic use)
• Severity of Illness Index
• Treatment Outcome